1 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Vitelliform Macular Dystrophy: new trials by email Literature Review of Vitelliform Macular Dystrophy trials Research Report on Vitelliform Macular Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) OPGx-BEST1 - ARB, BVMD | Phase 1 / Phase 2 | Recruiting | Opus Genetics, Inc | 10 | 2025-09-25 | 2026-09-24 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
Bestrophinopathy (1) · Myopia, Degenerative (1) · Polypoidal Choroidal Vasculopathy (1) · Pseudoxanthoma Elasticum (1) · Retinal Telangiectasis (1) · von Hippel-Lindau Disease (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Macular Degeneration (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Abnormalities, Multiple (1) · Angiomatosis (1) · Cardiovascular Diseases (1) · Choroid Diseases (1) · Choroidal Neovascularization (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Connective Tissue Diseases (1)
Ranibizumab (1)
Manhattan Eye, Ear & Throat Hospital (1) · Opus Genetics, Inc (1)
United States (2)